Bank of America
VIR icon

Bank of America’s Vir Biotechnology VIR Stock Holding History

Bank of America’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$11.6M Buy
1,142,539
+176,725
+18% +$1.68M ﹤0.01% 2934
2026
Q1 		$8.65M Buy
965,814
+34,906
+4% +$278K ﹤0.01% 3082
2025
Q4 		$5.61M Buy
930,908
+529,925
+132% +$3.16M ﹤0.01% 3298
2025
Q3 		$2.29M Sell
400,983
-24,718
-6% -$126K ﹤0.01% 4715
2025
Q2 		$2.15M Sell
425,701
-45,006
-10% -$241K ﹤0.01% 4714
2025
Q1 		$3.05M Buy
470,707
+277,057
+143% +$2.46M ﹤0.01% 4299
2024
Q4 		$1.42M Sell
193,650
-142,943
-42% -$1.13M ﹤0.01% 4743
2024
Q3 		$2.52M Sell
336,593
-515,181
-60% -$4.47M ﹤0.01% 4383
2024
Q2 		$7.58M Sell
851,774
-284,580
-25% -$2.73M ﹤0.01% 3220
2024
Q1 		$11.5M Buy
1,136,354
+984,009
+646% +$10M ﹤0.01% 2861
2023
Q4 		$1.53M Sell
152,345
-609,960
-80% -$5.57M ﹤0.01% 4634
2023
Q3 		$7.14M Buy
762,305
+421,403
+124% +$6.01M ﹤0.01% 3061
2023
Q2 		$8.36M Sell
340,902
-268,813
-44% -$6.75M ﹤0.01% 2881
2023
Q1 		$14.2M Buy
609,715
+99,862
+20% +$2.55M ﹤0.01% 2473
2022
Q4 		$12.9M Buy
509,853
+73,763
+17% +$1.81M ﹤0.01% 2438
2022
Q3 		$8.41M Buy
436,090
+239,146
+121% +$6.08M ﹤0.01% 2794
2022
Q2 		$5.02M Sell
196,944
-304,235
-61% -$7.1M ﹤0.01% 3395
2022
Q1 		$12.9M Buy
501,179
+197,274
+65% +$5.85M ﹤0.01% 2609
2021
Q4 		$12.7M Buy
303,905
+118,522
+64% +$4.64M ﹤0.01% 2688
2021
Q3 		$8.07M Sell
185,383
-48,291
-21% -$2.09M ﹤0.01% 3080
2021
Q2 		$11M Buy
233,674
+54,888
+31% +$2.5M ﹤0.01% 2729
2021
Q1 		$9.17M Buy
178,786
+132,998
+290% +$7.17M ﹤0.01% 2810
2020
Q4 		$1.23M Buy
45,788
+20,801
+83% +$676K ﹤0.01% 4330
2020
Q3 		$858K Sell
24,987
-21,369
-46% -$920K ﹤0.01% 4330
2020
Q2 		$1.9M Buy
46,356
+44,631
+2,587% +$1.5M ﹤0.01% 3668
2020
Q1 		$59K Buy
1,725
+609
+55% +$16.4K ﹤0.01% 5798
2019
Q4 		$14K Buy
+1,116
New +$15K ﹤0.01% 6586

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Bank of America's VIR Position: Q2 2026 in Review

Bank of America increased its Vir Biotechnology (VIR) stake by 18% in Q2 2026, buying an estimated $1.68M and bringing the position to 1,142,539 shares worth $11.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2934.

Bank of America first reported a position in VIR in Q4 2019 and has held it in 27 quarters since. The position peaked at $14.2M in Q1 2023. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Bank of America held 1,142,539 shares of Vir Biotechnology worth $11.6M as of Q2 2026.
  • Bank of America bought 176,725 Vir Biotechnology shares in Q2 2026, an estimated $1.68M.
  • Vir Biotechnology made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #2934 holding.
  • Bank of America first reported a position in Vir Biotechnology in Q4 2019 and has held it in 27 quarters since.
  • Bank of America's Vir Biotechnology position peaked at $14.2M in Q1 2023.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.